Maria Jesús Bullido Gómez-Heras

Researcher

Universidad Autónoma de Madrid
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Herpes simplex virus type 1 (HSV-1) has been proposed as an environmental risk factor for Alzheimer’s disease (AD). Viral infection of neuronal cells can reproduce hallmark pathological features of AD, including intracellular beta-amyloid (Aβ) accumulation, tau hyperphosphorylation, and lysosomal dysfunction. However, the molecular mechanisms underlying these alterations remain unclear, partly due to limitations of existing experimental models. Here, we established both two-dimensional (2D) and three-dimensional (3D) LUHMES neuronal cultures—a human mesencephalic-derived neural cell line that differentiates rapidly into mature neurons—to investigate HSV-1-induced AD-associated markers. Our results demonstrate that HSV-1 infection induces key features of AD, including intracellular accumulation of Aβ peptides and hyperphosphorylation of tau protein. Moreover, we observed disruptions in the autophagy–lysosome pathway, characterized by increased LC3-II levels, reduced cathepsin activity, and impaired lysosomal burden. Notably, these AD-like alterations were reproduced in 3D LUHMES neuronal aggregates, confirming their susceptibility to productive HSV-1 infection. Collectively, these findings indicate that HSV-1 not only triggers AD-like neuropathological markers but also disrupts cellular clearance mechanisms that may contribute to neuronal dysfunction and degeneration. This study validates the 3D LUHMES system as a useful human neuronal model to study virus-induced neurodegeneration and its mechanistic links to AD pathology.

Year:

2026

Herpes simplex virus type 1 (HSV-1) has been proposed as an environmental risk factor for Alzheimer’s disease (AD). Viral infection of neuronal cells can reproduce hallmark pathological features of AD, including intracellular beta-amyloid (Aβ) accumulation, tau hyperphosphorylation, and lysosomal dysfunction. However, the molecular mechanisms underlying these alterations remain unclear, partly due to limitations of existing experimental models. Here, we established both two-dimensional (2D) and three-dimensional (3D) LUHMES neuronal cultures—a human mesencephalic-derived neural cell line that differentiates rapidly into mature neurons—to investigate HSV-1-induced neurodegeneration. Our results demonstrate that HSV-1 infection induces key features of AD, including intracellular accumulation of Aβ peptides and hyperphosphorylation of tau protein. Moreover, we observed significant disruptions in the autophagy-lysosome pathway, characterized by increased LC3-II levels, reduced cathepsin activity, and impaired lysosomal burden. Notably, these AD-like alterations were reproduced in 3D LUHMES neuronal aggregates, confirming their susceptibility to productive HSV-1 infection. Collectively, these findings indicate that HSV-1 not only triggers classical AD-like neuropathological markers but also disrupts cellular clearance mechanisms that may contribute to neuronal dysfunction and degeneration. This study validates the 3D LUHMES system as a physiologically relevant human neuronal model to study virus-induced neurodegeneration and its mechanistic links to AD pathology.

Year:

2025

Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE , as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.

Year:

2025

Cholesterol, a crucial component of cell membranes, influences various biological processes, including membrane trafficking, signal transduction, and host-pathogen interactions. Disruptions in cholesterol homeostasis have been linked to congenital and acquired conditions, including neurodegenerative disorders such as Alzheimer’s disease (AD). Previous research from our group has demonstrated that herpes simplex virus type I (HSV-1) induces an AD-like phenotype in several cell models of infection. This study explores the interplay between cholesterol and HSV-1-induced neurodegeneration. The impact of cholesterol was determined by modulating its levels with methyl-beta-cyclodextrin (MβCD) using the neuroblastoma cell lines SK-N-MC and N2a. We have found that HSV-1 infection triggers the intracellular accumulation of cholesterol in structures resembling endolysosomal/autophagic compartments, a process reversible upon MβCD treatment. Moreover, MβCD exhibits inhibitory effects at various stages of HSV-1 infec-tion, underscoring the importance of cellular cholesterol levels not only in the viral entry pro-cess but also in subsequent post-entry stages. MβCD also alleviated several features of AD-like neurodegeneration induced by viral infection, including lysosomal impairment and intracellu-lar accumulation of amyloid-beta peptide (Aβ) and phosphorylated tau. In conclusion, these findings highlight the connection between cholesterol, neurodegeneration, and HSV-1 infection, providing valuable insights into the underlying mechanisms of AD.

Year:

2024

Background Mounting data suggests that herpes simplex virus type 1 (HSV-1) is involved in the pathogenesis of AD, possibly instigating amyloid-beta (Aβ) accumulation decades before the onset of clinical symptoms. However, human in vivo evidence linking HSV-1 infection to AD pathology is lacking in normal aging, which may contribute to the elucidation of the role of HSV-1 infection as a potential AD risk factor. Methods To shed light into this question, serum anti-HSV IgG levels were correlated with 18 F-Florbetaben-PET binding to Aβ deposits and blood markers of neurodegeneration (pTau181 and neurofilament light chain) in cognitively normal older adults. Additionally, we investigated whether associations between anti-HSV IgG and AD markers were more evident in APOE4 carriers. Results We showed that increased anti-HSV IgG levels are associated with higher Aβ load in fronto-temporal regions of cognitively normal older adults. Remarkably, these cortical regions exhibited abnormal patterns of resting state-functional connectivity (rs-FC) only in those individuals showing the highest levels of anti-HSV IgG. We further found that positive relationships between anti-HSV IgG levels and Aβ load, particularly in the anterior cingulate cortex, are moderated by the APOE4 genotype, the strongest genetic risk factor for AD. Importantly, anti-HSV IgG levels were unrelated to either subclinical cognitive deficits or to blood markers of neurodegeneration. Conclusions All together, these results suggest that HSV infection is selectively related to cortical Aβ deposition in normal aging, supporting the inclusion of cognitively normal older adults in prospective trials of antimicrobial therapy aimed at decreasing the AD risk in the aging population.

Year:

2024

Cholesterol, a crucial component of cell membranes, influences various biological processes, including membrane trafficking, signal transduction, and host-pathogen interactions. Disruptions in cholesterol homeostasis have been linked to congenital and acquired conditions, including neurodegenerative disorders such as Alzheimer’s disease (AD). Previous research from our group has demonstrated that herpes simplex virus type I (HSV-1) induces an AD-like phenotype in several cell models of infection. This study explores the interplay between cholesterol and HSV-1-induced neurodegeneration. The impact of cholesterol was determined by modulating its levels with methyl-beta-cyclodextrin (MβCD) using the neuroblastoma cell lines SK-N-MC and N2a. We have found that HSV-1 infection triggers the intracellular accumulation of cholesterol in structures resembling endolysosomal/autophagic compartments, a process reversible upon MβCD treatment. Moreover, MβCD exhibits inhibitory effects at various stages of HSV-1 infection, underscoring the importance of cellular cholesterol levels, not only in the viral entry process but also in subsequent post-entry stages. MβCD also alleviated several features of AD-like neurodegeneration induced by viral infection, including lysosomal impairment and intracellular accumulation of amyloid-beta peptide (Aβ) and phosphorylated tau. In conclusion, these findings highlight the connection between cholesterol, neurodegeneration, and HSV-1 infection, providing valuable insights into the underlying mechanisms of AD.

Year:

2024

Year:

2023

An increasing body of evidence strongly suggests that infections or reactivations of herpes simplex virus type 1 (HSV-1) may be closely linked to Alzheimer’s disease (AD). Promising results have been obtained using cell and animal models of HSV-1 infection, contributing to the understanding of the molecular mechanisms linking HSV-1 infection and AD neurodegeneration. ReNcell VM is a human neural stem cell line that has been used as a model system to study the impact of various infectious agents on the central nervous system. In this study, we demonstrate the suitability of the ReNcell VM cell line for developing a new in vitro model of HSV-1 infection. By following standard differentiation protocols, we were able to derive various nervous cell types, including neurons, astrocytes, and oligodendrocytes, from neural precursors. Additionally, we demonstrated the susceptibility of ReNcell VM cells, including precursor and differentiated cells, to HSV-1 infection and subsequent viral-induced AD-like neurodegeneration. Our findings support the use of this cell line to generate a new research platform for investigating AD neuropathology and its most significant risk factors, which may lead to important discoveries in the context of this highly impactful disease.

Year:

2023

Year:

2023

Collaborators (47)

Stefanie Heilmann-Heimbach

Head of Laboratory, Research Group Leader

University Hospital Bonn

GERMANY
View details

Pau Pastor

Institut Català de la Salut

SPAIN
View details

Eloy Rodriguez-Rodríguez

Instituto de Investigación Marqués de Valdecilla

SPAIN
View details

Henrik Zetterberg

Professor

University of Gothenburg

SWEDEN
View details

Agustín Ruiz Laza

Director of the Biology Core

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Harro Seelaar

Neurologist

Erasmus MC

NETHERLANDS
View details

Johannes Kornhuber

-

GERMANY
View details

Henne Holstege

Professor

KU Leuven

BELGIUM
View details

Markus Nöthen

Professor, Director

University Hospital Bonn

GERMANY
View details

Suzanne Schindler

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Pieter Jelle Visser

Karolinska Institutet

SWEDEN
View details

Jordi Pérez-Tur

Coordinador Adjunto al Área Global Vida

Agencia Estatal Consejo Superior de Investigaciones Científicas

SPAIN
View details

Jean-Charles Lambert

Head of research unit

INSERM

FRANCE
View details

Betty Tijms

Senior researcher

VU medisch centrum

NETHERLANDS
View details

Simon Laws

Professor

Edith Cowan University

AUSTRALIA
View details

Jonathan Vogelgsang

Harvard University

UNITED STATES
View details

Ciyang Wang

Washington University in St. Louis

UNITED STATES
View details

Timothy Hohman

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Pablo Mir

-

SPAIN
View details

Norbert Scherbaum

Professor for Clinical Addiction Research

University of Duisburg-Essen Faculty of Medizin

GERMANY
View details

Margda Waern

University of Gothenburg

SWEDEN
View details

Muhammad Ali

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Andrew Saykin

Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center

Indiana University School of Medicine

UNITED STATES
View details

Sami Heikkinen

Research Director

University of Eastern Finland

FINLAND
View details

Wiesje van der Flier

Scientific director

VU medisch centrum

NETHERLANDS
View details

David M. Holtzman

Washington University School of Medicine

UNITED STATES
View details

Jesus Aldudo

Universidad Autónoma de Madrid

SPAIN
View details

Dan Rujescu

Head of Clinical Division of General Psychiatry

Medical University of Vienna

AUSTRIA
View details

Virginia M-Y Lee

Professor

University of Pennsylvania

UNITED STATES
View details

Lourdes Martorell

Researcher

Universitat Rovira i Virgili

SPAIN
View details

Robert Perneczky

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Martin Ingelsson

Specialist

Uppsala University Hospital

SWEDEN
View details

Hilkka Soininen

Kuopio University Hospital

FINLAND
View details

Riccardo E Marioni

University of Edinburgh

UNITED KINGDOM
View details

Alison Goate

Professor and Chair

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Alfredo Ramirez

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Josefa Girona

Research support/PhD

Universitat Rovira i Virgili

SPAIN
View details

Carlos Cruchaga

Professor

Washington University in St. Louis

UNITED STATES
View details

Ville Leinonen

Professor

University of Eastern Finland

FINLAND
View details

Lutz Froelich

Head

Zentralinstitut für Seelische Gesundheit

GERMANY
View details

Rebecca Sims

Senior Research Fellow

Cardiff University

UNITED KINGDOM
View details

Montse Guardiola

Tenure-track 2 lecturer

Universitat Rovira i Virgili

SPAIN
View details

Lars Bertram

Professor of Genome Analytics

University of Lübeck

GERMANY
View details

Cornelia Van Duijn

Professor

University of Oxford

UNITED KINGDOM
View details

Alberto Lleó

Director

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Sterling Johnson

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Menghan Liu

Washington University in St. Louis

UNITED STATES
View details